Ensuring safe conduct and compliance in research
The Brandeis University Institutional Biosafety Committee (IBC) oversees the safe conduct of research involving infectious agents, select agents and recombinant DNA technology. The committee ensures compliance with the National Institutes of Health (NIH) Guidelines and the Center for Disease Control and Prevention (CDC).
All faculty, staff, students or users of the facilities at Brandeis University who are contemplating use of recombinant DNA research must comply with these guidelines. All protocols in which recombinant DNA will be used, regardless of the funding source, must be submitted to the Institutional Biosafety Committee for review.
The IBC is composed of faculty investigators with expertise in rDNA and biohazard research, an environmental health and safety expert, an independent scientific consultant, an administrator, and members of the community.